If you would like to hear about future studies or updates directly from Beacon Therapeutics, you can sign up by calling 1-855-843-9847.
What is the LANDSCAPE trial?
The LANDSCAPE trial is studying an investigational (not yet FDA-approved) new gene therapy called laru-zova (also named AGTC-501) for male patients between the ages of 12 and 50 who have X-linked retinitis pigmentosa (XLRP) caused by a mutation (or defect) in the RPGR gene.
The purpose of the LANDSCAPE trial is to assess the safety and tolerability of laru-zova administered in both eyes.
XLRP is an inherited rare genetic eye disease in which light-sensitive cells in the retina (the thin layer of tissue that lines the inner surface of the back of the eye) do not function correctly.
XLRP can be caused by a mutation in a gene called Retinitis Pigmentosa GTPase Regulator (RPGR).
A change in RPGR can result in loss of vision due to degeneration (breakdown) of special cells in the retina called photoreceptors, which are needed for vision.
The LANDSCAPE trial is for males between the ages of 12 and 50 who have X-linked retinitis pigmentosa (XLRP) caused by a mutation (or defect) in the RPGR gene. Individuals must meet certain criteria to qualify for the study.
You or your child may be eligible for the LANDSCAPE trial if:
Diagnosed with XLRP and have RPGR gene mutation (confirmed by genetic testing)
Best corrected Visual Acuity between 20/32 and 20/300 in BOTH eyes
